Evidence map›Paper›PMID 37434264›Full record

ReviewJournal of biological engineering2023

Clinical utility of mesenchymal stem/stromal cells in regenerative medicine and cellular therapy.

Vitali V Maldonado, Neel H Patel, Emma E Smith, C Lowry Barnes, Michael P Gustafson, Raj R Rao, Rebekah M Samsonraj

Open access · goldAbstract readReview
In one paragraph

Review in Journal of biological engineering, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed
26.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 93 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Special Issue "Biomedical Applications of Mesenchymal Stem Cells".International journal of molecular sciences · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Vitali V MaldonadoDepartment of Biomedical Engineering, University of Arkansas, 790 W Dickson St, Fayetteville, AR, USA.
Neel H PatelDepartment of Biomedical Engineering, University of Arkansas, 790 W Dickson St, Fayetteville, AR, USA.
Emma E SmithDepartment of Biomedical Engineering, University of Arkansas, 790 W Dickson St, Fayetteville, AR, USA.
C Lowry BarnesDepartment of Orthopedic Surgery, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Michael P GustafsonNyberg Human Cellular Therapy Laboratory, Mayo Clinic, Phoenix, AZ, USA.
Raj R RaoDepartment of Biomedical Engineering, University of Arkansas, 790 W Dickson St, Fayetteville, AR, USA.
Rebekah M SamsonrajDepartment of Biomedical Engineering, University of Arkansas, 790 W Dickson St, Fayetteville, AR, USA. rmsamson@uark.edu.
University of Arkansas at Fayetteville · USMayo Clinic in Florida · USUniversity of Arkansas for Medical Sciences · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stem/stromal cells (MSCs) have been carefully examined to have tremendous potential in regenerative medicine. With their immunomodulatory and regenerative properties, MSCs have numerous applications within the clinical sector. MSCs have the properties of multilineage differentiation, paracrine signaling, and can be isolated from various tissues, which makes them a key candidate for applications in numerous organ systems. To accentuate the importance of MSC therapy for a range of clinical indications, this review highlights MSC-specific studies on the musculoskeletal, nervous, cardiovascular, and immune systems where most trials are reported. Furthermore, an updated list of the different types of MSCs used in clinical trials, as well as the key characteristics of each type of MSCs are included. Many of the studies mentioned revolve around the properties of MSC, such as exosome usage and MSC co-cultures with other cell types. It is worth noting that MSC clinical usage is not limited to these four systems, and MSCs continue to be tested to repair, regenerate, or modulate other diseased or injured organ systems. This review provides an updated compilation of MSCs in clinical trials that paves the way for improvement in the field of MSC therapy.

Indexed as

CardiovascularClinical trialsImmune system disordersMesenchymal stem/stromal cellsMSCsMusculoskeletalNervous systemRegenerative medicine

Identifiers

PMID37434264
PMCPMC10334654
OpenAlexW4383878354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.